Ensysce Biosciences To Present Oral Overdose Protection For Opioids At The 5th Annual NIH HEAL Meeting
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences, Inc. (ENSC) announced that its Chief Commercial Officer will present a poster on PF614-MPAR, an opioid with abuse deterrent and overdose protection, at the NIH HEAL Meeting. PF614-MPAR has received Breakthrough Therapy Designation from the FDA and funding from NIDA. The company aims to address the opioid crisis with its TAAP and MPAR platforms, offering safer medications for severe pain treatment.
January 25, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences will present its lead product PF614-MPAR at the NIH HEAL Meeting, highlighting its unique abuse deterrent and overdose protection properties. The product has received FDA Breakthrough Therapy Designation and NIDA funding, indicating significant regulatory support and potential for accelerated development.
The presentation at the NIH HEAL Meeting and the FDA Breakthrough Therapy Designation for PF614-MPAR are strong positive indicators for Ensysce Biosciences. These developments are likely to generate investor interest and could positively impact ENSC's stock price in the short term due to the potential accelerated development and market interest in innovative solutions to the opioid crisis.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100